Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18894999 | 0.84 | — | — | |
| SCHEMBL18907373 | 0.83 | ALDH1A1 (0.35) | — | |
| SCHEMBL19369287 | 0.82 | ALDH1A1 (0.31) | — | |
| SCHEMBL18907651 | 0.81 | LMNA (0.38) | LMNA | |
| SCHEMBL18909862 | 0.80 | MAPT (0.39) | LMNA | |
| SCHEMBL18907521 | 0.76 | ACACA (0.31) | — | |
| SCHEMBL18907561 | 0.72 | MEN1 (0.30) | — | |
| SCHEMBL18888723 | 0.72 | ADORA2A (0.36) | LMNA | |
| SCHEMBL18907824 | 0.71 | ACACA (0.43) | — | |
| SCHEMBL18908168 | 0.71 | ACACA (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170166584-A1 | TRIAZOLE ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. | 2017-06-15 | — | — | US | disclosed |
| WO-2017091617-A1 | TRIAZOLE ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC (US) | 2017-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166584-A1 | TRIAZOLE ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT1 | LMNA 3901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.